ZEPJURNI Trademark

Trademark Overview


On Thursday, April 16, 2020, a trademark application was filed for ZEPJURNI with the United States Patent and Trademark Office. The USPTO has given the ZEPJURNI trademark a serial number of 88874321. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 27, 2024. This trademark is owned by Eli Lilly and Company. The ZEPJURNI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis
zepjurni

General Information


Serial Number88874321
Word MarkZEPJURNI
Filing DateThursday, April 16, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 27, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 23, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 27, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, April 20, 2020NEW APPLICATION ENTERED
Monday, April 27, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, July 8, 2020ASSIGNED TO EXAMINER
Wednesday, July 8, 2020SUSPENSION LETTER WRITTEN
Wednesday, February 3, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 23, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, July 8, 2020LETTER OF SUSPENSION E-MAILED
Wednesday, July 8, 2020NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, January 21, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, February 23, 2021PUBLISHED FOR OPPOSITION
Wednesday, August 18, 2021SOU EXTENSION 1 FILED
Tuesday, April 20, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, August 18, 2021SOU TEAS EXTENSION RECEIVED
Monday, August 23, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, August 23, 2021SOU EXTENSION 1 GRANTED
Friday, September 23, 2022SOU TEAS EXTENSION RECEIVED
Friday, September 23, 2022SOU EXTENSION 3 FILED
Friday, September 23, 2022SOU EXTENSION 3 GRANTED
Tuesday, August 24, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 16, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, March 16, 2022SOU EXTENSION 2 FILED
Thursday, March 17, 2022SOU EXTENSION 2 GRANTED
Friday, March 18, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 27, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 18, 2023SOU TEAS EXTENSION RECEIVED
Monday, March 13, 2023SOU TEAS EXTENSION RECEIVED
Monday, March 13, 2023SOU EXTENSION 4 FILED
Monday, March 13, 2023SOU EXTENSION 4 GRANTED
Wednesday, March 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 18, 2023SOU EXTENSION 5 FILED
Tuesday, September 19, 2023SOU EXTENSION 5 GRANTED
Monday, May 27, 2024ABANDONMENT - NO USE STATEMENT FILED
Friday, July 12, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Wednesday, September 20, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED